Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2 amplified gastric cancer (GC) cell lines

Authors :: Fortunato Ciardiello
E. Martinelli
Angelica Petrillo
A. Diana
Valentina Belli
F. Morgillo
Maria Maddalena Laterza
Luca Pompella
Vincenza Ciaramella
F. De Vita
B. Savastano
Michele Orditura
Jole Ventriglia
Giuseppe Tirino
Source :: Annals of Oncology. 27:iv24
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Oncology
business.industry
Cell culture
Cancer research
Medicine
Cancer
Hematology
business
medicine.disease

Full Text Access

Tools